CAMBRIDGE, Mass., March 22, 2017 – Semma Therapeutics, a biopharmaceutical company developing Stem Cell-derived Islet therapy for type 1 diabetes (T1D), today announced it has received an investment from the JDRF T1D Fund, a venture philanthropy fund exclusively devoted to finding and funding the best early-stage T1D commercial opportunities. Financial terms of the investment were not disclosed.

Read more

CAMBRIDGE, Mass., November 7, 2016 – Semma Therapeutics, a biopharmaceutical company developing cellular therapies for the treatment of diabetes, announced today that Mark Fishman, M.D., has joined its Board of Directors as Chairman.

Read more

CAMBRIDGE, Mass., September 12 th , 2016 – Semma Therapeutics, a biopharmaceutical company developing cellular therapy for diabetes, announced today that it has accepted a $5 million grant from the California Institute of Regenerative Medicine (CIRM). The award provides funding to develop personalized cell therapy for the treatment of diabetes. Diabetic patients’ own cells will be collected, transformed first into stem cells and then differentiated into stem-cell derived pancreatic islets (SC-islets) to use as an investigational cell therapy for diabetes.

Read more

When his son Sam was diagnosed with type 1 diabetes at six months of age, Doug Melton was incredulous. “I remember at night, my wife and I pricking his heel, and saying ‘No, this can’t be, this can’t be,’” he says. “It felt like we had lost the lottery.”

Read more

In a step that could lead to a new diabetes treatment, several Boston-area hospitals have teamed up with the Harvard Stem Cell Institute and biotech Semma Therapeutics to make personalized cell-based therapies and organize clinical trials.

Read more

The Harvard Stem Cell Institute (HSCI), three of Harvard’s clinical affiliates, and a biopharmaceutical company have formed an unusual collaboration to establish the Boston Autologous Islet Replacement Program (BAIRT) to accelerate a cure for diabetes.

Read more

A Cambridge, Mass., company, Semma Therapeutics, has acquired Providence-based CytoSolv, Inc., which has garnered local support since its founding in 2010 from the Slater Technology Fund and others, Slater announced Monday.

Read more

Semma aims to create a beta cell device implant for Type 1 diabetes patients that could provide them with 5 to 7 years of insulin independence. The notion of beta cell replacement therapy is not a new one. The breakthrough that led to the creation of Semma was the ability to generate sufficient and well-functioning human pancreatic beta cells from undifferentiated pluripotent stem cells.

Read more

CAMBRIDGE, Mass., March 18, 2015 – Semma Therapeutics, a company developing a cell therapy for Type 1 diabetes, announced today that it has closed a $44 million Series A consisting of equity financing and strategic funding. The Series A financing is led by MPM Capital, with Fidelity Biosciences, ARCH Venture Partners, and Medtronic participating. Alongside the equity financing, Semma entered into an undisclosed agreement with Novartis Pharmaceuticals.

Read more
14 October 2014 Published in Videos Written by

Big development in treatment of Type 1 diabetes

VIDEO:  In this video, CBS discusses the discoveries made by Semma Therapeutics co-founders in treating type 1 diabetes.

Read more

In this article published by Pagliuca et al., scientists describe how to generate functional human pancreatic beta cells from stem cells.

Read more
16 November 2013 Published in Videos Written by

Harnessing the Potential of Stem Cells

VIDEO:  Semma co-founder Dr. Douglas Melton makes a presentation on the potential for new medicines from stem cell research.

Read more
15 June 2013 Published in Publications Written by

How to make a functional beta cell

In this article published by Pagliuca et al., scientists describe how to generate functional human pancreatic beta cells from stem cells.

Read more